Table 3.
Changes in response to 5 mo of gonadotropin releasing hormone agonist therapy plus add-back of placebo or estradiol, with or without resistance exercise training
| GnRHAG+PL |
GnRHAG+E2 |
|||
|---|---|---|---|---|
| No exercise (n = 16) | Exercise (n = 8) | No exercise (n = 16) | Exercise (n = 5) | |
| Weight, kg | −0.6 (−1.8,+0.7) | −1.0 (−2.5,+0.5) | 1.1 (+0.3,+1.9) | 1.6 (−2.2,+5.4) |
| Fat mass, kg | 0.2 (−0.9,+1.4) | −1.0 (−2.2,+0.2) | 0.9 (+0.1,+1.6) | 0.1 (−1.7,+1.9) |
| Fat-free mass, kg | −0.8 (−1.3,-0.3) | 0.1 (−0.9,+0.9) | 0.2 (−0.3,+0.8) | 1.5 (−0.8,+3.7) |
| Estradiol, pg/ml | −82.3 (−141.9,−22.7)a | −48.8 (−77.7,−19.7) | 44.6 (−6.9,+96.2)a | 199.0 (−200.0,+598.0)b |
| REE, kcal/d | −37.8 (−88.7,+13.0) | −87.2 (−185.9,+11.4) | 14.6 (−34.8,+64.0) | −19.3 (−95.1+56.4) |
| TEE, kcal/min | −108.8 (−201.1,−16.5) | −166.5 (−388.1,+55.1) | 92.7 (−167.1,−18.4) | −107.4 (−298.3,+83.5) |
Values are means (95% CI). GnRHAG+PL, GnRH agonist treatment + placebo; GnRHAG+E2, GnRH agonist treatment + estradiol; REE, resting energy expenditure; TEE, total energy expenditure.
a
n = 13;
b
n = 4.